메뉴 건너뛰기




Volumn 53, Issue 5, 2013, Pages 532-539

Addition of cilostazol to conventional dual antiplatelet therapy reduces the risk of cardiac events and restenosis after drug-eluting stent implantation: A meta-analysis

Author keywords

Cilostazol; Drug eluting stents; Late loss; Major adverse cardiac events; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL;

EID: 84880176964     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.64     Document Type: Article
Times cited : (12)

References (33)
  • 1
    • 36348952607 scopus 로고    scopus 로고
    • Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents
    • DOI 10.1161/CIRCULATIONAHA.107.707331
    • Doyle B, Rihal CS, O'Sullivan CJ, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation. 2007;116(21): 2391-2398. (Pubitemid 350145074)
    • (2007) Circulation , vol.116 , Issue.21 , pp. 2391-2398
    • Doyle, B.1    Rihal, C.S.2    O'Sullivan, C.J.3    Lennon, R.J.4    Wiste, H.J.5    Bell, M.6    Bresnahan, J.7    Holmes Jr., D.R.8
  • 2
    • 78651412362 scopus 로고    scopus 로고
    • Drug-eluting stents versus bare-metal stents in saphenous vein graft interventions: A systematic review and meta-analysis
    • Wiisanen ME, Abdel-Latif A, Mukherjee D, Ziada KM. Drug-eluting stents versus bare-metal stents in saphenous vein graft interventions: a systematic review and meta-analysis. JACC Cardiovasc Interv. 2010;3(12):1262-1273.
    • (2010) JACC Cardiovasc Interv , vol.3 , Issue.12 , pp. 1262-1273
    • Wiisanen, M.E.1    Abdel-Latif, A.2    Mukherjee, D.3    Ziada, K.M.4
  • 5
    • 67650755016 scopus 로고    scopus 로고
    • Safety and efficacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies
    • Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009; 119(25):3198-3206.
    • (2009) Circulation. , vol.119 , Issue.25 , pp. 3198-3206
    • Kirtane, A.J.1    Gupta, A.2    Iyengar, S.3
  • 6
    • 77952948745 scopus 로고    scopus 로고
    • Long-term outcomes following coronary drug-eluting- and baremetal- stent implantation
    • Auer J, Leitner A, Berent R, Lamm G, Lassnig E, Krennmair G. Long-term outcomes following coronary drug-eluting- and baremetal- stent implantation. Atherosclerosis. 2010;210(2):503-509.
    • (2010) Atherosclerosis , vol.210 , Issue.2 , pp. 503-509
    • Auer, J.1    Leitner, A.2    Berent, R.3    Lamm, G.4    Lassnig, E.5    Krennmair, G.6
  • 7
    • 51749094385 scopus 로고    scopus 로고
    • Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention
    • Solinas E, Dangas G, Kirtane AJ, et al. Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention. Am J Cardiol. 2008;102(3):311-315.
    • (2008) Am J Cardiol , vol.102 , Issue.3 , pp. 311-315
    • Solinas, E.1    Dangas, G.2    Kirtane, A.J.3
  • 10
    • 8344221349 scopus 로고    scopus 로고
    • Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
    • Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004; 109(25):3171-3175.
    • (2004) Circulation , vol.109 , Issue.25 , pp. 3171-3175
    • Matetzky, S.1    Shenkman, B.2    Guetta, V.3
  • 11
    • 51649108832 scopus 로고    scopus 로고
    • Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty- Platelet Reactivity Predicts Outcome) study
    • Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty- Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol. 2008;52(14):1128-1133.
    • (2008) J Am Coll Cardiol , vol.52 , Issue.14 , pp. 1128-1133
    • Patti, G.1    Nusca, A.2    Mangiacapra, F.3    Gatto, L.4    D'Ambrosio, A.5    Di Sciascio, G.6
  • 12
    • 59849120163 scopus 로고    scopus 로고
    • Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up
    • Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009;119(2):237-242.
    • (2009) Circulation. , vol.119 , Issue.2 , pp. 237-242
    • Marcucci, R.1    Gori, A.M.2    Paniccia, R.3
  • 13
    • 0028070508 scopus 로고
    • Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells
    • DOI 10.1016/0006-2952(94)90062-0
    • Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF, Polson JB. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol. 1994;48(4):827-835. (Pubitemid 24283854)
    • (1994) Biochemical Pharmacology , vol.48 , Issue.4 , pp. 827-835
    • Pan, X.1    Arauz, E.2    Krzanowski, J.J.3    Fitzpatrick, D.F.4    Polson, J.B.5
  • 14
    • 20144384243 scopus 로고    scopus 로고
    • Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F
    • Kim MJ, Park KG, Lee KM, et al. Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension. 2005;45(4):552-556.
    • (2005) Hypertension , vol.45 , Issue.4 , pp. 552-556
    • Kim, M.J.1    Park, K.G.2    Lee, K.M.3
  • 15
    • 78249237183 scopus 로고    scopus 로고
    • Inhibitory effects of cilostazol on proliferation of vascular smooth muscle cells (VSMCs) through suppression of the ERK1/2 pathway
    • Yoo AR, Koh SH, Cho GW, Kim SH. Inhibitory effects of cilostazol on proliferation of vascular smooth muscle cells (VSMCs) through suppression of the ERK1/2 pathway. J Atheroscler Thromb. 2010;17 (10):1009-1018.
    • (2010) J Atheroscler Thromb , vol.17 , Issue.10 , pp. 1009-1018
    • Yoo, A.R.1    Koh, S.H.2    Cho, G.W.3    Kim, S.H.4
  • 18
    • 0342955606 scopus 로고    scopus 로고
    • Effects of cilostazol on angiographic restenosis after coronary stent placement
    • Park SW, Lee CW, Kim HS, et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol. 2000;86(5):499-503.
    • (2000) Am J Cardiol , vol.86 , Issue.5 , pp. 499-503
    • Park, S.W.1    Lee, C.W.2    Kim, H.S.3
  • 19
    • 34548633702 scopus 로고    scopus 로고
    • Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial)
    • Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol. 2007;100(7): 1103-1108.
    • (2007) Am J Cardiol , vol.100 , Issue.7 , pp. 1103-1108
    • Lee, S.W.1    Park, S.W.2    Kim, Y.H.3
  • 20
    • 79952435293 scopus 로고    scopus 로고
    • A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: Results from the DECLARELONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial
    • Lee SW, Park SW, Kim YH, et al. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARELONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol. 2011;57(11):1264-1270.
    • (2011) J Am Coll Cardiol. , vol.57 , Issue.11 , pp. 1264-1270
    • Lee, S.W.1    Park, S.W.2    Kim, Y.H.3
  • 21
    • 78651287537 scopus 로고    scopus 로고
    • Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: Results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy on ischemic complication after drugeluting stenT implantation) trial
    • Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drugeluting stenT implantation) trial. J Am Coll Cardiol. 2011;57(3): 280-289.
    • (2011) J Am Coll Cardiol , vol.57 , Issue.3 , pp. 280-289
    • Suh, J.W.1    Lee, S.P.2    Park, K.W.3
  • 22
    • 44349138210 scopus 로고    scopus 로고
    • Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention
    • Biondi-Zoccai GG, Lotrionte M, Anselmino M, et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J. 2008;155(6):1081-1089.
    • (2008) Am Heart J. , vol.155 , Issue.6 , pp. 1081-1089
    • Biondi-Zoccai, G.G.1    Lotrionte, M.2    Anselmino, M.3
  • 23
    • 67650935286 scopus 로고    scopus 로고
    • Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: An evidence-based approach to answering a clinical query
    • Singh I, Shafiq N, Pandhi P, et al. Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query. Br J Clin Pharmacol. 2009;68(1):4-13.
    • (2009) Br J Clin Pharmacol , vol.68 , Issue.1 , pp. 4-13
    • Singh, I.1    Shafiq, N.2    Pandhi, P.3
  • 24
    • 77955428270 scopus 로고    scopus 로고
    • Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: A meta-analysis
    • Jennings DL, Kalus JS. Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis. J Clin Pharmacol. 2010;50(4):415-421.
    • (2010) J Clin Pharmacol , vol.50 , Issue.4 , pp. 415-421
    • Jennings, D.L.1    Kalus, J.S.2
  • 25
    • 40749126089 scopus 로고    scopus 로고
    • Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation in Diabetic Patients)
    • Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol. 2008;51(12):1181-1187.
    • (2008) J Am Coll Cardiol , vol.51 , Issue.12 , pp. 1181-1187
    • Lee, S.W.1    Park, S.W.2    Kim, Y.H.3
  • 26
    • 62949165644 scopus 로고    scopus 로고
    • Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study
    • Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J. 2009;157(4):733-739.
    • (2009) Am Heart J , vol.157 , Issue.4 , pp. 733-739
    • Han, Y.1    Li, Y.2    Wang, S.3
  • 27
    • 0037030658 scopus 로고    scopus 로고
    • Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization
    • Morice MC, Serruys PW, Sousa JE, et al. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346(23):1773-1780.
    • (2002) N Engl J Med , vol.346 , Issue.23 , pp. 1773-1780
    • Morice, M.C.1    Serruys, P.W.2    Sousa, J.E.3
  • 28
    • 0037422604 scopus 로고    scopus 로고
    • Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions
    • DOI 10.1161/01.CIR.0000047700.58683.A1
    • Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107(1):38-42. (Pubitemid 36070930)
    • (2003) Circulation , vol.107 , Issue.1 , pp. 38-42
    • Grube, E.1    Silber, S.2    Hauptmann, K.E.3    Mueller, R.4    Buellesfeld, L.5    Gerckens, U.6    Russell, M.E.7
  • 29
    • 0032968970 scopus 로고    scopus 로고
    • Cilostazol
    • DOI 10.2165/00002512-199914010-00005
    • Sorkin EM, Markham A. Cilostazol. Drugs Aging. 1999;14(1): 63-71. (Pubitemid 29050247)
    • (1999) Drugs and Aging , vol.14 , Issue.1 , pp. 63-71
    • Sorkin, E.M.1    Markham, A.2
  • 30
    • 0037114872 scopus 로고    scopus 로고
    • Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication
    • DOI 10.1016/S0002-9149(02)02869-2, PII S0002914902028692
    • Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90(12):1314-1319. (Pubitemid 35449476)
    • (2002) American Journal of Cardiology , vol.90 , Issue.12 , pp. 1314-1319
    • Thompson, P.D.1    Zimet, R.2    Forbes, W.P.3    Zhang, P.4
  • 31
    • 15244356877 scopus 로고    scopus 로고
    • Comparison of cilostazol and clopidogrel after successful coronary stenting
    • Lee SW, Park SW, Hong MK, et al. Comparison of cilostazol and clopidogrel after successful coronary stenting. Am J Cardiol. 2005;95(7):859-862.
    • (2005) Am J Cardiol. , vol.95 , Issue.7 , pp. 859-862
    • Lee, S.W.1    Park, S.W.2    Hong, M.K.3
  • 32
    • 24644465504 scopus 로고    scopus 로고
    • Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent [3]
    • Wessely R, Kastrati A, Schömig A. Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. Ann Intern Med. 2005;143(5):392-394. (Pubitemid 41266615)
    • (2005) Annals of Internal Medicine , vol.143 , Issue.5 , pp. 392-394
    • Wessely, R.1    Kastrati, A.2    Schomig, A.3
  • 33
    • 27644555633 scopus 로고    scopus 로고
    • Triple versus dual antiplatelet therapy after coronary stenting: Impact on stent thrombosis
    • Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005;46(10):1833-1837.
    • (2005) J Am Coll Cardiol , vol.46 , Issue.10 , pp. 1833-1837
    • Lee, S.W.1    Park, S.W.2    Hong, M.K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.